An International Phase 3, Randomized, Double-Blind, Placebo- and Active (Tolterodine)-Controlled Multicenter Study to Evaluate the Safety and Efficacy of Vibegron in Patients With Symptoms of Overactive Bladder
Trial Snapshot
- Phase
- Phase 3
- Status
- Completed
- Sponsor
- Urovant Sciences GmbH
- Enrollment
- 1,530
- Locations
- 204
- Primary Endpoint
- Change From Baseline (CFB) at Week 12 in the Average Number of Micturitions Per 24 Hours in All Overactive Bladder (OAB) Participants
Study Overview
Brief Summary
This study is designed to evaluate the safety, tolerability, and efficacy of vibegron administered once daily in patients with OAB.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Has a history of OAB for at least 3 months prior to the Screening Visit.
- •Meets either the OAB Wet or OAB Dry criteria.
Exclusion Criteria
- •Urology Medical History
- •Patient had an average total daily urine volume > 3000 mL in the past 6 months or during the 14-day Run-in Period.
- •Has lower urinary tract pathology that could, in the opinion of the Investigator, be responsible for urgency, frequency, or incontinence.
- •Has a history of surgery to correct stress urinary incontinence, pelvic organ prolapse, or procedural treatments for BPH within 6 months of Screening.
- •Has current history or evidence of Stage 2 or greater pelvic organ prolapse (prolapse extends beyond the hymenal ring).
- •Patient is currently using a pessary for the treatment of pelvic organ prolapse.
- •Has a known history of elevated post-void residual volume defined as greater than 150 mL.
- •Has undergone bladder training or electrostimulation within 28 days prior to Screening or plans to initiate either during the study.
- •Has an active or recurrent (> 3 episodes per year) urinary tract infection by clinical symptoms or pre-defined laboratory criteria.
- •Has a requirement for an indwelling catheter or intermittent catheterization.
- •Has received an intradetrusor injection of botulinum toxin within 9 months prior to Screening.
- •Has uncontrolled hyperglycemia (defined as fasting blood glucose > 150 mg/dL or 8.33 mmol/L and/or non-fasting blood glucose > 200 mg/dL or 11.1 mmol/L) or, if in the opinion of the Investigator, is uncontrolled.
- •Has evidence of diabetes insipidus.
- •Is pregnant, breast-feeding, or is planning to conceive within the projected duration of the study.
- •Has a concurrent malignancy or history of any malignancy within 5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
- •Has uncontrolled hypertension (systolic blood pressure of ≥ 180 mmHg and/or diastolic blood pressure of ≥ 100 mmHg) or has a resting heart rate (by pulse) > 100 beats per minute.
- •Has narrow angle glaucoma (primary open angle glaucoma is not excluded).
- •Has a history of cerebral vascular accident, transient ischemic attack, unstable angina, myocardial infarction, coronary artery interventions (e.g., coronary artery bypass grafting or percutaneous coronary interventions [e.g., angioplasty, stent insertion]), or neurovascular interventions (e.g., carotid artery stenting) within 6 months prior to the Screening Visit. Has a known history of liver disease.
- •Has a history of injury, surgery, or neurodegenerative diseases (e.g., multiple sclerosis, Parkinson's) that could affect the lower urinary tract or its nerve supply.
- •Has hematuria, including microscopic hematuria according to pre-defined criteria.
- •Has clinically significant electrocardiogram (ECG) abnormality.
- •Has alanine aminotransferase or aspartate aminotransferase > 2.0 times the upper limit of normal (ULN), or bilirubin (total bilirubin) > 1.5 x ULN (or > 2.0 x ULN if secondary to Gilbert syndrome or pattern consistent with Gilbert syndrome).
- •Has an estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m
- •Has an allergy, intolerance, or a history of a significant clinical or laboratory adverse experience associated with any of the active or inactive components of the vibegron formulation or tolterodine formulation.
- •Is currently participating or has participated in a study with an investigational compound or device within 28 days prior to signing informed consent, or has participated in any previous study with vibegron.
Arms & Interventions
Placebo to match vibegron + Placebo to match Tolterodine
Intervention: Vibegron placebo (Drug)
Vibegron + Placebo to match Tolterodine
Intervention: Tolterodine placebo (Drug)
Vibegron + Placebo to match Tolterodine
Intervention: vibegron (Drug)
Tolterodine + Placebo to match vibegron
Intervention: Tolterodine Tartrate ER (Drug)
Tolterodine + Placebo to match vibegron
Intervention: Vibegron placebo (Drug)
Placebo to match vibegron + Placebo to match Tolterodine
Intervention: Tolterodine placebo (Drug)
Outcomes
Primary Outcomes
Change From Baseline (CFB) at Week 12 in the Average Number of Micturitions Per 24 Hours in All Overactive Bladder (OAB) Participants
Time Frame: Baseline (BL); Week 12
A micturition/void is defined as "Urinated in Toilet" as indicated on the Patient Voiding Diary (PVD). The number of micturitions is defined as the number of times a participant voided in the toilet as indicated on the PVD. The average daily number of micturitions was calculated using the daily entries in the PVD (which was to be completed prior to each study visit) as the total number of micturitions that occurred on a Complete Diary Day (CDD) divided by the number of CDDs in the PVD. CFB was calculated as the post-BL value minus the BL value. "Per 24 hours" corresponds to one Diary Day (i.e., time between when the participant got up for the day each morning and time the participant got up for the day the next morning as recorded in the PVD). Covariates included in the mixed model for repeated measures are study visit (Weeks 2, 4, 8, and 12), OAB type (wet/dry), sex, region (U.S./non-U.S.), BL number of micturitions, and treatment by study visit interaction. FAS=Full Analysis Set.
CFB at Week 12 in the Average Number of Urge Urinary Incontinence (UUI) Episodes Per 24 Hours in OAB Wet Participants
Time Frame: Baseline; Week 12
The number of UUI episodes is defined as the number of times a participant had checked "urge" as the main reason for the leakage in the PVD, regardless of whether more than one reason for leakage in addition to "urge" was checked. The average daily number of UUI episodes was calculated using the daily entries in the PVD (which was to be completed prior to each study visit) as the total number of UUI episodes that occurred on a CDD divided by the number of CCDs in the PVD. CFB was calculated as the post-BL value minus the BL value. "Per 24 hours" corresponds to one Diary Day (i.e., time between when participant got up for the day each morning and time participant got up for the day the next morning as recorded in the PVD). Covariates included in the mixed model for repeated measures were study visit (Weeks 2, 4, 8, and 12), sex, region (U.S./non-U.S.), BL number of UUI episodes and treatment by study visit interaction. FAS-I=Full Analysis Set for Incontinence.
Secondary Outcomes
- CFB at Week 12 in the Average Number of Urgency Episodes Over 24 Hours in All OAB Participants(Baseline; Week 12)
- Percentage of OAB Wet Participants With at Least a 75% Reduction From Baseline in UUI Episodes Per 24 Hours at Week 12(Baseline; Week 12)
- Percentage of OAB Wet Participants With a 100% Reduction From Baseline in UUI Episodes Per 24 Hours at Week 12(Baseline; Week 12)
- Percentage of All OAB Participants With at Least a 50% Reduction From Baseline in Urgency Episodes Per 24 Hours at Week 12(Baseline; Week 12)
- CFB at Week 12 in the Average Number of Total Incontinence Episodes Over 24 Hours in OAB Wet Participants(Baseline; Week 12)
- CFB at Week 12 in the Coping Score From the Overactive Bladder Questionnaire Long Form (OAB-q LF, 1-week Recall) in All OAB Participants(Baseline; Week 12)
- CFB at Week 12 in the Average Volume Voided Per Micturition in All OAB Participants(Baseline; Week 12)
- CFB at Week 12 in the Health-related Quality of Life (HRQL) Total Score From the OAB-q LF (1-week Recall) in All OAB Participants(Baseline; Week 12)
- CFB at Week 12 in the Symptom Bother Score From the OAB-q LF (1-week Recall) in All OAB Participants(Baseline; Week 12)
- Percentage of All OAB Participants With an Average Number of Micturitions < 8 Per 24 Hours at Week 12(Week 12)
- Percentage of OAB Wet Participants With at Least a 50% Reduction From Baseline in Total Incontinence Episodes Per 24 Hours at Week 12(Baseline; Week 12)
- CFB at Week 12 in Overall Bladder Symptoms Based on Patient Global Impression of Severity (PGI-Severity) in All OAB Participants(Baseline; Week 12)
- CFB at Week 12 in Overall Control Over Bladder Symptoms Based on Patient Global Impression of Control (PGI-Control) in All OAB Participants(Baseline; Week 12)